Table 2. Renal characteristics and primary renal diagnoses, by trial and diabetes status.
| Overall | Prior DM | No prior DM | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | EMPA-KIDNEY | EMPA-KIDNEY | DAPA-CKD | CREDENCE | EMPA-KIDNEY | DAPA-CKD | ||
| Number randomized | 6609 | 3039 | 2906 | 4401 | 3570 | 1398 | ||
| eGFR (mL/min/1.73 m2) | ||||||||
| Mean (SD) | 37.5 (14.8) | 36.0 (13.9) | 43.8 (12.6) | 56.2 (18.2) | 38.7 (15.4) | 41.7 (11.7) | ||
| uACR (mg/g) | ||||||||
| Median (IQR) | 412 (94–1190) | 348 (68–1293) | 1017 | 927 (463–1833) | 461 (128–1117) | 861 | ||
| Primary renal diagnosis | ||||||||
| Diabetic nephropathy/diabetic kidney disease | 2057 (31) | 2057 (68) | 2510 (86) | 4401 (100) | 0 (0) | 0 (0) | ||
| Hypertensive/renovascular disease | 1445 (22) | 401 (13) | 203 (7) | 1044 (29) | 494 (35) | |||
| Any glomerular disease | 1669 (25) | 172 (6) | 97 (3) | 1497 (42) | 598 (43) | |||
| IgA nephropathy | 817 (12) | 59 (2) | 38 (1) | 758 (21) | 232 (17) | |||
| Focal segmental glomerulosclerosis | 195 (3) | 34 (1) | 22 (1) | 161 (5) | 93 (7) | |||
| Membranous nephropathy | 96 (1) | 13 (<1) | 10 (<1) | 83 (2) | 33 (2) | |||
| Minimal change disease | 14 (<1) | 4 (< 1) | 2 (< 1) | 10 (<1) | 9 (1) | |||
| Other glomerular disease | 547 (8) | 62 (2) | 25 (1) | 485 (14) | 231 (17) | |||
| Other | 808 (12) | 203 (7) | 49 (2) | 605 (17) | 139 (10) | |||
| Tubulointerstitial disease (including obstructive) | 468 (7) | 101 (3) | 30 (1) | 367 (10) | 117 (8) | |||
| Other known | 340 (5) | 102 (3) | 19 (1) | 238 (7) | 22 (2) | |||
| Unknown | 630 (10) | 206 (7) | 47 (2) | 424 (12) | 167 (12) | |||
| Prior kidney biopsy | 1862 (28) | 354 (12) | 373 (13) | 1508 (42) | 500 (36) | |||
Values are presented as n (%) unless stated otherwise.
Sources: CREDENCE: N Engl J Med 2019;380:2295–306; DAPA-CKD: NDT 2020;35:1700–11 and Lancet Diabetes Endocrinol 2021;9:22–31.